Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation (ENSURE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01232335
First received: October 31, 2010
Last updated: May 28, 2013
Last verified: May 2013

October 31, 2010
May 28, 2013
January 2010
May 2013   (final data collection date for primary outcome measure)
Incidence of Adverse Events [ Time Frame: Range of one year ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01232335 on ClinicalTrials.gov Archive Site
  • The level of asthma control under long-term use [ Time Frame: At the end of 24 weeks ] [ Designated as safety issue: No ]
  • The level of asthma control under long-term use [ Time Frame: At the end of one year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation
Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation for Long-term Use

The purpose of this study is to confirm the safety profile for long term treatment and maximize doses and the control status on bronchial asthma in daily clinical usage

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients treated with Symbicort for the first time due to bronchial asthma

Bronchial Asthma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1500
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients treated with Symbicort for the first time possibly at the higher dose due to bronchial asthma

Exclusion Criteria:

-

Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT01232335
D589IC00001
No
AstraZeneca
AstraZeneca
Not Provided
Study Director: Yoshida Shigeru AstraZeneca K.K.
AstraZeneca
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP